Related Experiment Video

Updated: Jun 11, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing

Elio Coletta1, Salvatore Coppolino, Febronia Federico

  • 1UOC Pediatria e UTIN, PO Barone I. Romeo, Patti, Messina, Italy.

Italian Journal of Pediatrics
|July 9, 2010
PubMed

Insights

Coordinating respiratory syncytial virus (RSV) prophylaxis delivery using vial sharing and cohorting infants reduced costs by 29.2% and prevented hospitalizations. This optimized care model ensures effective immunization and improves the cost-benefit of palivizumab.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract infections in infants.
  • High-risk infants may experience fatal outcomes or require intensive care unit admission.
  • Infant RSV infection is linked to an increased risk of developing asthma later in life.

Purpose of the Study:

  • To optimize the delivery of respiratory syncytial virus (RSV) prophylaxis during the 2008-2009 season.
  • To minimize drug costs associated with prophylaxis through innovative logistical strategies.
  • To ensure all eligible infants receive timely and effective immunization against RSV.

Main Methods:

  • Implemented a coordinated prophylaxis delivery system.
  • Utilized vial sharing and infant cohorting strategies to reduce waste and costs.
  • Employed a Visual Basic programming system for software-based coordination.

Main Results:

  • Achieved a significant cost saving of 29.2% compared to the theoretical drug requirement.
  • Successfully prevented any infant hospitalizations due to respiratory syncytial virus (RSV) infection during the study period.
  • Demonstrated the effectiveness of the coordinated care model in managing RSV prophylaxis.

Conclusions:

  • The developed model ensures comprehensive immunization for all patients, enhancing the cost-benefit of palivizumab prophylaxis.
  • This optimized care delivery model offers a practical and effective approach for other healthcare institutions.
  • Highlights the importance of strategic planning in managing infectious disease prophylaxis and improving patient outcomes.
Abstract

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...